Literature DB >> 28263888

Combined venomics, antivenomics and venom gland transcriptome analysis of the monocoled cobra (Naja kaouthia) from China.

Ning Xu1, Hong-Yan Zhao1, Yin Yin1, Shan-Shan Shen1, Lin-Lin Shan1, Chuan-Xi Chen1, Yan-Xia Zhang1, Jian-Fang Gao2, Xiang Ji3.   

Abstract

We conducted an omics-analysis of the venom of Naja kaouthia from China. Proteomics analysis revealed six protein families [three-finger toxins (3-FTx), phospholipase A2 (PLA2), nerve growth factor, snake venom metalloproteinase (SVMP), cysteine-rich secretory protein and ohanin], and venom-gland transcriptomics analysis revealed 28 protein families from 79 unigenes. 3-FTx (56.5% in proteome/82.0% in transcriptome) and PLA2 (26.9%/13.6%) were identified as the most abundant families in venom proteome and venom-gland transcriptome. Furthermore, N. kaouthia venom expressed strong lethality (i.p. LD50: 0.79μg/g) and myotoxicity (CK: 5939U/l) in mice, and showed notable activity in PLA2 but weak activity in SVMP, l-amino acid oxidase or 5' nucleotidase. Antivenomic assessment revealed that several venom components (nearly 17.5% of total venom) from N. kaouthia could not be thoroughly immunocaptured by commercial Naja atra antivenom. ELISA analysis revealed that there was no difference in the cross-reaction between N. kaouthia and N. atra venoms against the N. atra antivenom. The use of commercial N. atra antivenom in treatment of snakebites caused by N. kaouthia is reasonable, but design of novel antivenom with the attention on enhancing the immune response of non-immunocaptured components should be encouraged. BIOLOGICAL SIGNIFICANCE: The venomics, antivenomics and venom-gland transcriptome of the monocoled cobra (Naja kaouthia) from China have been elucidated. Quantitative and qualitative differences are evident when venom proteomic and venom-gland transcriptomic profiles are compared. Two protein families (3-FTx and PLA2) are found to be the predominated components in N. kaouthia venom, and considered as the major players in functional role of venom. Other protein families with relatively low abundance appear to be minor in the functional significance. Antivenomics and ELISA evaluation reveal that the N. kaouthia venom can be effectively immunorecognized by commercial N. atra antivenom, but still a small number of venom components could not be thoroughly immunocaptured. The findings indicate that exploring the precise composition of snake venom should be executed by an integrated omics-approach, and elucidating the venom composition is helpful in understanding composition-function relationships and will facilitate the clinical application of antivenoms.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antivenomics; Enzymatic activity; Naja kaouthia; Toxicological activity; Transcriptome; Venomics

Mesh:

Substances:

Year:  2017        PMID: 28263888     DOI: 10.1016/j.jprot.2017.02.018

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  20 in total

Review 1.  Computational Studies of Snake Venom Toxins.

Authors:  Paola G Ojeda; David Ramírez; Jans Alzate-Morales; Julio Caballero; Quentin Kaas; Wendy González
Journal:  Toxins (Basel)       Date:  2017-12-22       Impact factor: 4.546

Review 2.  A Review and Database of Snake Venom Proteomes.

Authors:  Theo Tasoulis; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2017-09-18       Impact factor: 4.546

Review 3.  Antibody Cross-Reactivity in Antivenom Research.

Authors:  Line Ledsgaard; Timothy P Jenkins; Kristian Davidsen; Kamille Elvstrøm Krause; Andrea Martos-Esteban; Mikael Engmark; Mikael Rørdam Andersen; Ole Lund; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-09-27       Impact factor: 4.546

4.  Evaluating the Performance of De Novo Assembly Methods for Venom-Gland Transcriptomics.

Authors:  Matthew L Holding; Mark J Margres; Andrew J Mason; Christopher L Parkinson; Darin R Rokyta
Journal:  Toxins (Basel)       Date:  2018-06-19       Impact factor: 4.546

5.  An overview of Phoneutria nigriventer spider venom using combined transcriptomic and proteomic approaches.

Authors:  Marcelo R V Diniz; Ana L B Paiva; Clara Guerra-Duarte; Milton Y Nishiyama; Mauricio A Mudadu; Ursula de Oliveira; Márcia H Borges; John R Yates; Inácio de L Junqueira-de-Azevedo
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

Review 6.  Malaysian Cobra Venom: A Potential Source of Anti-Cancer Therapeutic Agents.

Authors:  Syafiq Asnawi Zainal Abidin; Yee Qian Lee; Iekhsan Othman; Rakesh Naidu
Journal:  Toxins (Basel)       Date:  2019-02-01       Impact factor: 4.546

7.  Exploring the Diversity and Novelty of Toxin Genes in Naja sumatrana, the Equatorial Spitting Cobra from Malaysia through De Novo Venom-Gland Transcriptomics.

Authors:  Ho Phin Chong; Kae Yi Tan; Nget Hong Tan; Choo Hock Tan
Journal:  Toxins (Basel)       Date:  2019-02-11       Impact factor: 4.546

8.  Convergent evolution of pain-inducing defensive venom components in spitting cobras.

Authors:  T D Kazandjian; D Petras; S D Robinson; J van Thiel; H W Greene; K Arbuckle; A Barlow; D A Carter; R M Wouters; G Whiteley; S C Wagstaff; A S Arias; L-O Albulescu; A Plettenberg Laing; C Hall; A Heap; S Penrhyn-Lowe; C V McCabe; S Ainsworth; R R da Silva; P C Dorrestein; M K Richardson; J M Gutiérrez; J J Calvete; R A Harrison; I Vetter; E A B Undheim; W Wüster; N R Casewell
Journal:  Science       Date:  2021-01-22       Impact factor: 47.728

9.  Venom-gland transcriptomic, venomic, and antivenomic profiles of the spine-bellied sea snake (Hydrophis curtus) from the South China Sea.

Authors:  Hong-Yan Zhao; Lin Wen; Yu-Feng Miao; Yu Du; Yan Sun; Yin Yin; Chi-Xian Lin; Long-Hui Lin; Xiang Ji; Jian-Fang Gao
Journal:  BMC Genomics       Date:  2021-07-08       Impact factor: 3.969

Review 10.  Studying Smaller and Neglected Organisms in Modern Evolutionary Venomics Implementing RNASeq (Transcriptomics)-A Critical Guide.

Authors:  Björn Marcus von Reumont
Journal:  Toxins (Basel)       Date:  2018-07-16       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.